revumenib (SNDX-5613) / Syndax Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123
  • ||||||||||  Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] NUP98/NSD1-POSITIVE AML IS ADDICTED TO A FUNCTIONAL MENIN-MLL INTERACTION () -  May 13, 2021 - Abstract #EHA2021EHA_898;    
    Notably, we found that and its potential target gene FLT3 are uniformly downregulated in a dose dependent manner suggesting an impact of this drug on a secondary leukaemic driver. Conclusion This study demonstrates the relevance of the Menin-MLL interaction for NUP98/NSD1-driven leukemogenesis in primary patient cells and highlights the pharmacologic inhibition of this interaction as a promising therapeutic option for this poor prognosis AML.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] MENIN INHIBITION DECREASES BCL-2 AND SYNERGIZES WITH VENETOCLAX IN NPM1/FLT3-MUTATED AML () -  May 13, 2021 - Abstract #EHA2021EHA_895;    
    Aims To investigate the anti-leukemic activity and potential synergism and mechanisms of the combination of the menin-MLL1 inhibitor SDNX-50469, an equipotent surrogate of the clinical compound SNDX-5613 and venetoclax in vivo in an NPM1c/FLT3-ITD/TKD patient-derived xenograft (PDX) model...Conclusion Our study further validated menin as a therapeutic target and demonstrated that its inhibition synergizes with venetoclax in NPM1/FLT3-mutated AML, which warrants further clinical evaluation. Inhibition of FLT3 may further enhance the therapeutic efficacy of menin and Bcl-2 co-targeting in NPM1 and FLT3 mutated AML.